|
1
|
Coiffier B, Thieblemont C, Van Den Neste
E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M,
Sebban C, et al: Long-term outcome of patients in the LNH-98.5
trial, the first randomized study comparing rituximab-CHOP to
standard CHOP chemotherapy in DLBCL patients: A study by the Groupe
d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Friedberg JW: Relapsed/refractory diffuse
large B-cell lymphoma. Hematology Am Soc Hematol Educ Program.
2011:498–505. 2011.PubMed/NCBI
|
|
3
|
Ehsanian R, Van Waes C and Feller SM:
Beyond DNA binding-a review of the potential mechanisms mediating
quinacrine's therapeutic activities in parasitic infections,
inflammation, and cancers. Cell Commun Signal. 9:132011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Preet R, Mohapatra P, Mohanty S, Sahu SK,
Choudhuri T, Wyatt MD and Kundu CN: Quinacrine has anticancer
activity in breast cancer cells through inhibition of topoisomerase
activity. Int J Cancer. 130:1660–1670. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang W, Ho WC, Dicker DT, MacKinnon C,
Winkler JD, Marmorstein R and El-Deiry WS: Acridine derivatives
activate p53 and induce tumor cell death through Bax. Cancer Biol
Ther. 4:893–898. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gallant JN, Allen JE, Smith CD, Dicker DT,
Wang W, Dolloff NG, Navaraj A and El-Deiry WS: Quinacrine
synergizes with 5-fluorouracil and other therapies in colorectal
cancer. Cancer Biol Ther. 12:239–251. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jani TS, DeVecchio J, Mazumdar T, Agyeman
A and Houghton JA: Inhibition of NF-kappaB signaling by quinacrine
is cytotoxic to human colon carcinoma cell lines and is synergistic
in combination with tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem.
285:19162–19172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Friedman J, Nottingham L, Duggal P, Pernas
FG, Yan B, Yang XP, Chen Z and Van Waes C: Deficient TP53
expression, function, and cisplatin sensitivity are restored by
quinacrine in head and neck cancer. Clin Cancer Res. 13:6568–6578.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Y, Bi Q, Dong L, Li X, Ge X, Zhang X,
Fu J, Wu D and Li S: Quinacrine enhances cisplatin-induced
cytotoxicity in four cancer cell lines. Chemotherapy. 56:127–134.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang W, Gallant JN, Katz SI, Dolloff NG,
Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A and
El-Deiry WS: Quinacrine sensitizes hepatocellular carcinoma cells
to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 12:229–238.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu X, Wang Y, Wang H, Wang Q, Wang L, Miao
J, Cui F and Wang J: Quinacrine inhibits cell growth and induces
apoptosis in human gastric cancer cell line SGC-7901. Curr Ther Res
Clin Exp. 73:52–64. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park SM, Deering RP, Lu Y, Tivnan P,
Lianoglou S, Al-Shahrour F, Ebert BL, Hacohen N, Leslie C, Daley
GQ, et al: Musashi-2 controls cell fate, lineage bias, and TGF-β
signaling in HSCs. J Exp Med. 211:71–87. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhong W, Feder JN, Jiang MM, Jan LY and
Jan YN: Asymmetric localization of a mammalian numb homolog during
mouse cortical neurogenesis. Neuron. 17:43–53. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo M, Jan LY and Jan YN: Control of
daughter cell fates during asymmetric division: Interaction of Numb
and Notch. Neuron. 17:27–41. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu Y, Xu W, Ji J, Feng D, Sourbier C, Yang
Y, Qu J, Zeng Z, Wang C, Chang X, et al: Alternative splicing of
the cell fate determinant Numb in hepatocellular carcinoma.
Hepatology. 62:1122–1131. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gurova K: New hopes from old drugs:
Revisiting DNA-binding small molecules as anticancer agents. Future
Oncol. 5:1685–1704. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Neznanov N, Gorbachev AV, Neznanova L,
Komarov AP, Gurova KV, Gasparian AV, Banerjee AK, Almasan A,
Fairchild RL and Gudkov AV: Anti-malaria drug blocks proteotoxic
stress response: Anti-cancer implications. Cell Cycle. 8:3960–3970.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo C, Gasparian AV, Zhuang Z, Bosykh DA,
Komar AA, Gudkov AV and Gurova KV: 9-Aminoacridine-based anticancer
drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.
Oncogene. 28:1151–1161. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gurova KV, Hill JE, Guo C, Prokvolit A,
Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M,
Tararova ND, et al: Small molecules that reactivate p53 in renal
cell carcinoma reveal a NF-kappaB-dependent mechanism of p53
suppression in tumors. Proc Natl Acad Sci USA. 102:17448–17453.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mohapatra P, Preet R, Das D, Satapathy SR,
Choudhuri T, Wyatt MD and Kundu CN: Quinacrine-mediated autophagy
and apoptosis in colon cancer cells is through a p53- and
p21-dependent mechanism. Oncol Res. 20:81–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Preet R, Mohapatra P, Das D, Satapathy SR,
Choudhuri T, Wyatt MD and Kundu CN: Lycopene synergistically
enhances quinacrine action to inhibit Wnt-TCF signaling in breast
cancer cells through APC. Carcinogenesis. 34:277–286. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dermawan JK, Gurova K, Pink J, Dowlati A,
De S, Narla G, Sharma N and Stark GR: Quinacrine overcomes
resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle
progression in non-small cell lung cancer. Mol Cancer Ther.
13:2203–2214. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Changchien JJ, Chen YJ, Huang CH, Cheng
TL, Lin SR and Chang LS: Quinacrine induces apoptosis in human
leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and
suppression of ERK/c-Jun-mediated BCL2L1 expression. Toxicol Appl
Pharmacol. 284:33–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Preet R, Siddharth S, Satapathy SR, Das S,
Nayak A, Das D, Wyatt MD and Kundu CN: Chk1 inhibitor synergizes
quinacrine mediated apoptosis in breast cancer cells by
compromising the base excision repair cascade. Biochem Pharmacol.
105:23–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barbouti A, Höglund M, Johansson B, Lassen
C, Nilsson PG, Hagemeijer A, Mitelman F and Fioretos T: A novel
gene, MSI2, encoding a putative RNA-binding protein is recurrently
rearranged at disease progression of chronic myeloid leukemia and
forms a fusion gene with HOXA9 as a result of the cryptic
t(7;17)(p15;q23). Cancer Res. 63:1202–1206. 2003.PubMed/NCBI
|
|
26
|
Kawahara H, Imai T, Imataka H, Tsujimoto
M, Matsumoto K and Okano H: Neural RNA-binding protein Musashi1
inhibits translation initiation by competing with eIF4G for PABP. J
Cell Biol. 181:639–653. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Imai T, Tokunaga A, Yoshida T, Hashimoto
M, Mikoshiba K, Weinmaster G, Nakafuku M and Okano H: The neural
RNA-binding protein Musashi1 translationally regulates mammalian
numb gene expression by interacting with its mRNA. Mol Cell Biol.
21:3888–3900. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kong DS, Kim MH, Park WY, Suh YL, Lee JI,
Park K, Kim JH and Nam DH: The progression of gliomas is associated
with cancer stem cell phenotype. Oncol Rep. 19:639–643.
2008.PubMed/NCBI
|
|
29
|
Siddall NA, McLaughlin EA, Marriner NL and
Hime GR: The RNA-binding protein Musashi is required intrinsically
to maintain stem cell identity. Proc Natl Acad Sci USA.
103:8402–8407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang XY, Yin Y, Yuan H, Sakamaki T, Okano
H and Glazer RI: Musashi1 modulates mammary progenitor cell
expansion through proliferin-mediated activation of the Wnt and
Notch pathways. Mol Cell Biol. 28:3589–3599. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sureban SM, May R, George RJ, Dieckgraefe
BK, McLeod HL, Ramalingam S, Bishnupuri KS, Natarajan G, Anant S
and Houchen CW: Knockdown of RNA binding protein musashi-1 leads to
tumor regression in vivo. Gastroenterology. 134:1448–1458. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mu Q, Wang Y, Chen B, Qian W, Meng H, Tong
H, Chen F, Ma Q, Ni W, Chen S and Jin J: High expression of
Musashi-2 indicates poor prognosis in adult B-cell acute
lymphoblastic leukemia. Leuk Res. 37:922–927. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aly RM and Ghazy HF: Prognostic
significance of MSI2 predicts unfavorable outcome in adult B-acute
lymphoblastic leukemia. Int J Lab Hematol. 37:272–278. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sheng W, Dong M, Chen C, Li Y, Liu Q and
Dong Q: Musashi2 promotes the development and progression of
pancreatic cancer by down-regulating Numb protein. Oncotarget.
8:14359–14373. 2017.PubMed/NCBI
|
|
35
|
Wierstra I and Alves J: The c-myc
promoter: Still MysterY and challenge. Adv Cancer Res. 99:113–333.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Valera A, López-Guillermo A,
Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S,
Espinosa I, Novelli S, Briones J, Mate JL, et al: MYC protein
expression and genetic alterations have prognostic impact in
patients with diffuse large B-cell lymphoma treated with
immunochemotherapy. Haematologica. 98:1554–1562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Han Y, Ye A, Zhang Y, Cai Z, Wang W, Sun
L, Jiang S, Wu J, Yu K and Zhang S: Musashi-2 silencing exerts
potent activity against acute myeloid leukemia and enhances
chemosensitivity to daunorubicin. PLoS One. 10:e01364842015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sima J, Zhang B, Yu Y, Sima X and Mao Y:
Overexpression of Numb suppresses growth, migration, and invasion
of human clear cell renal cell carcinoma cells. Tumour Biol.
36:2885–2892. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schweinfest CW, Fujiwara S, Lau LF and
Papas TS: c-myc can induce expression of G0/G1 transition genes.
Mol Cell Biol. 8:3080–3087. 1988. View Article : Google Scholar : PubMed/NCBI
|
